Matches 1 - 42 out of 42


Match Document Document Title
US20110091450 METHODS FOR TREATING DISSEMINATED INTRAVASCULAR COAGULATION BY INHIBITING MASP-2 DEPENDENT COMPLEMENT ACTIVATION  
In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. In one embodiment, the invention provides methods of treating...
US20130004480 CD20 Binding Molecules for the Treatment of Copd  
Use of CD20 binding molecules, such as anti-CD20 antibodies, for the treatment of chronic obstructive pulmonary disease (COPD).
US20130340105 Human SIRPAalpha Transgenic Animals and Their Methods of Use  
The invention relates generally to compositions and methods of using transgenic non-human animals expressing human SIRPα that are engrafted with a human hematopoietic system. In various...
US20140017228 HUMANIZED LIGHT CHAIN MICE  
Non-human animals, tissues, cells, and genetic material are provided that comprise a modification of an endogenous non-human heavy chain immunoglobulin sequence and that comprise an ADAM6 activity...
US20130160153 Humanized Light Chain Mice  
Non-human animals, tissues, cells, and genetic material are provided that comprise a modification of an endogenous non-human heavy chain immunoglobulin sequence and that comprise an ADAM6 activity...
US20070248596 Transgenic Ficus, Method for Producing Same and Use Thereof  
The present invention relates to transgenic Ficus plants, particularly Ficus carica (fig tree), to a method for producing same, and to Ficus plants, plant materials and plant products produced by...
US20100183589 HUMAN BLOOD PROTEINS EXPRESSED IN MONOCOT SEEDS  
The invention is directed to blood proteins produced in monocot seeds and isolated therefrom for use in therapeutic compositions, and to methods of making these isolated blood proteins and to...
US20080299112 Human Polyclonal Antibodies from Genetically Engineered Animals  
Substantially human antisera are provided by genetically modifying a domestic animal generally weighing at least about 1 kg. The domestic animal is genetically modified by generating inactive...
US20080124323 Nutritional Composition Comprising Indigestible Oligosaccharides  
The present invention provides a method and composition for the treatment and/or prevention of respiratory tract infection and/or respiratory tract infection disease, said method comprising orally...
US20140037616 IMMUNOGLOBULIN 1  
The present invention relates to a method for the generation of single chain immunoglobulins in a mammal. In particular, the present invention relates to a method for the generation of single...
US20050079170 Dimeric and multimeric antigen binding structure  
The present invention relates to dimeric and multimeric antigen binding structures, expression vectors encoding said structures, and diagnostic, as well as therapeutic, uses of said structures....
US20060134099 Production of rabies antibodies in plants  
Human rabies monoclonal antibodies (rabies MAbP) comprising rabies human MAb S057 heavy chain and light chain subunits are expressed and assembled in plants under the control of two strong...
US20120288493 METHOD OF INHIBITNG COMPLEMENT ACTIVATION WITH HUMAN ANTI-FACTOR C3 ANTIBODIES AND USE THEREOF  
A method of inhibiting complement activation mediated by C3b inhibitors in a subject includes administering a C3B inhibitor to the subject to inhibit at least one of C3b binding to factors B and...
US20140023637 Methods of Modifying Eukaryotic Cells  
A method for engineering and utilizing large DNA vectors to target, via homologous recombination, and modify, in any desirable fashion, endogenous genes and chromosomal loci in eukaryotic cells....
US20140017229 Methods of Modifying Eukaryotic Cells  
A method for engineering and utilizing large DNA vectors to target, via homologous recombination, and modify, in any desirable fashion, endogenous genes and chromosomal loci in eukaryotic cells....
US20100297110 ANTIBODY SPECIFIC FOR HUMAN IL-4 FOR THE TREATMENT OF CANCER  
The present invention relates to the use of an antibody or an antigen-binding fragment thereof with specific binding activity for human interleukin-4 for the prevention and/or treatment of cancer.
US20130089539 KIM-1 ANTIBODIES FOR TREATMENT OF TH2-MEDIATED CONDITIONS  
Compositions and methods for treating Th2- and Th1-mediated disease are provided.
US20120114635 ANTIBODIES TO CROSS-LINKED AMYLOID BETA OLIGOMERS  
The invention relates to antibodies that bind cross-linked amyloid β oligomers, and methods for using such antibodies for diagnosis and treatment of Alzheimer's disease.
US20050079183 Compounds having reduced immunogenicity and a method of reducing the immunogenicity of compounds  
Reduced-immunogenic fusion compounds are disclosed. The fusion compounds of the invention comprise immunogenic compounds linked to auto-antigenic sequences which render the compound less...
US20120034207 PRODUCTION OF HER RECEPTOR ANTIBODIES IN PLANT  
A method of making an antibody in plants that binds to a HER receptor is described. The antibody preferably contains sequences from trastuzumab that have been optimized for expression in plants.
US20090220494 Antibodies produced in a transgenic avian  
The invention includes compositions comprising novel forms of glycosylated human interferon-α.
US20050074450 Compositions comprising neisseria meningitidis antigens from serogroups b and c  
International patent application WO99/61053 discloses immunogenic compositions that comprise N. meningitidis serogroup C oligosaccharide conjugated to a carrier, in combination with N....
US20090053210 Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals  
The present invention describes transgenic animals with human(ized) immunoglobulin loci and transgenes encoding human(ized) Igα and/or Igβ sequences. Of particular interest are animals with...
US20070258978 Immunogenic Recombinant Antibody  
The invention refers to an immunogenic recombinant antibody designed for immunization of primates comprising at least a part of a murine IgG2a subtype amino acid sequence and a mammalian...
US20130345405 BINDING MOLECULES  
The present invention relates to the manufacture of a diverse repertoire of functional heavy chain-only antibodies that undergo affinity maturation, and uses thereof. The invention also relates to...
US20130344057 BINDING MOLECULES  
The present invention relates to the manufacture of a diverse repertoire of functional heavy chain-only antibodies that undergo affinity maturation, and uses thereof. The invention also relates to...
US20140068796 TRANSGENIC ANIMAL FOR PRODUCTION OF ANTIBODIES HAVING MINIMAL CDRS  
A transgenic animal is provided. In certain embodiments, the transgenic animal comprises a genome comprising: an immunoglobulin light chain locus comprising: a) a functional immunoglobulin light...
US20070264257 Immunotherapy of autoimmune disorders  
Compositions and methods for treating autoimmune diseases are described. In particular, the use of B cell depleting agents and cytotoxic drug/B cell depleting agent conjugates with a drug loading...
US20100303806 Avian derivedantibodies  
The invention encompasses among other things antibodies including cytotoxic antibodies such as anti-CD20 having avian N-linked glycosylation patterns obtained from egg white of eggs laid by...
US20090186017 Graft-Versus-Host Disease Predicting Marker and Use Thereof  
A test method that provides data useful in predicting the probability of onset of acute graft-versus-host disease (GVHD) is described along with a kit for performing the method, and a...
US20140041067 ANTIBODIES, VARIABLE DOMAINS & CHAINS TAILORED FOR HUMAN USE  
The invention relates to the provision of antibody therapeutics and prophylactics that are tailored specifically for human use. The present invention provides libraries, vertebrates and cells,...
US20080118501 Antibodies with enhanced antibody-dependent cellular cytotoxicity activity, methods of their production and use  
The invention relates, in part, to antibodies with increased ADCC activity. Methods of producing such antibodies are also provided. The antibodies of the invention are produced in mammary...
US20090041761 Method of immunizing animal, composition for immunization, method for producing antibody, method for producing hybridoma and method for producing monoclonal antibody  
It is an object of the present invention to a method whereby a humoral immune response is induced more efficiently in producing an antibody against an antigen protein by gene immunization. A...
US20140134156 ANIMAL MODELS AND THERAPEUTIC MOLECULES  
The invention discloses methods for the generation of chimaeric human-non-human antibodies and chimaeric antibody chains, antibodies and antibody chains so produced, and derivatives thereof...
US20100310552 Antibodies produced in the avian oviduct  
The invention relates to transgenic avians which produce antibodies in the egg white by introducing a nucleic acid sequence into the genome of an avian embryo wherein the nucleic acid sequence...
US20120117670 HUMANIZED AXL ANTIBODIES  
The present invention refers to monoclonal humanized antibodies, which bind to the extracellular domain of the AXL receptor tyrosine kinase and which at least partially inhibit AXL activity.
US20100272715 VARIABLE ANTIBODIES  
The present invention discloses inhibitory antibodies against Factor VIII with modified glycosylation, either by enzymatic deglycosylation or by site directed mutagenesis. Said antibodies with...
US20050226863 Single-domain antibodies and uses thereof  
The invention relates in part to methods of making single-domain antibodies and methods of using single-domain antibodies to diagnose and treat disease. The invention also relates to methods and...
US20140248261 ANTIBODY AGAINST MUTANT ALPHA-ACTININ-4  
An antibody against mutant α-actinin-4 having an amino acid sequence with at least one amino acid residue substitution in the region between position 245 and 263 in the amino acid sequence of...
US20170121402 ORAL COMPOSITION OF ANTI-TNF ALPHA ANTIBODIES  
The present invention relates to a pharmaceutical composition for oral delivery, including an anti tumour necrosis factor alpha (TNFα) antibody, preferably a monoclonal antibody produced in the...
US20170044250 Antibodies, Uses & Methods  
The present invention relates to anti-human OX40L antibodies, new medical uses and methods.
US20150307595 HUMAN POLYCLONAL ANTIBODIES FROM GENETICALLY ENGINEERED ANIMALS  
Substantially human antisera are provided by genetically modifying a domestic animal generally weighing at least about 1 kg. The domestic animal is genetically modified by generating inactive...

Matches 1 - 42 out of 42